Log In
Print
BCIQ
Print
Print this Print this
 

ALN-CC5

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionRNAi therapeutic targeting complement 5 (C5)
Molecular Target Complement 5 (C5)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentIND
Standard Indication Hematology (unspecified)
Indication DetailsTreat complement-mediated diseases; Treat paroxysmal nocturnal hemoglobinuria (PNH)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today